Biotechnology Precision Medicine Law In Russia.
1. Introduction
Precision medicine is an advanced branch of biotechnology and healthcare that uses an individual's genetic information, biological characteristics, medical history, lifestyle and environmental factors to identify the most appropriate method of disease prevention, diagnosis and treatment.
Unlike conventional medicine, which often applies similar treatment protocols to patients with the same diagnosis, precision medicine seeks to tailor medical interventions to the characteristics of each individual.
In Russia, precision medicine is connected with several developing areas:
Genomic sequencing and genetic diagnostics.
Pharmacogenomics and personalised drug selection.
Precision oncology and targeted cancer therapies.
Biomarker-based diagnosis.
Stem-cell and regenerative medicine.
Personalised vaccines and immunotherapy.
Artificial intelligence-assisted diagnosis.
Biobanking and genetic-data management.
Predictive medicine and hereditary disease prevention.
Personalised reproductive and prenatal medicine.
An important legal qualification: Russia does not have one comprehensive federal statute called the Precision Medicine Act. Instead, precision medicine is governed through a combination of healthcare, pharmaceutical, personal-data, genetic-engineering, laboratory-diagnostic and biomedical-cellular-product legislation.
The central legal challenge is to balance biotechnology innovation with patient consent, medical safety, genetic privacy, scientific reliability and professional accountability.
2. Constitutional foundations of precision medicine
The Constitution of the Russian Federation provides the general constitutional framework for personalised healthcare.
| Constitutional provision | Legal significance |
|---|---|
| Article 20 | Right to life |
| Article 21 | Protection of human dignity |
| Article 23 | Privacy and personal confidentiality |
| Article 24 | Protection against unlawful collection and use of personal information |
| Article 41 | Right to health protection and medical assistance |
These provisions are relevant when a hospital collects genetic information, conducts molecular diagnostics, recommends personalised treatment or processes a patient's biological samples.
For example, a hospital conducting genomic testing to determine whether a patient is genetically predisposed to a particular cancer must consider the patient's privacy, informed consent and applicable medical-confidentiality requirements.
3. Principal legislation governing precision medicine
The Russian regulatory framework consists of several important federal laws.
A. Federal Law No. 323-FZ of 21 November 2011 – On the Fundamentals of Health Protection of Citizens
This is the principal general healthcare statute.
It establishes the legal framework for:
Medical diagnosis and treatment.
Patient rights.
Informed voluntary consent.
Medical confidentiality.
Medical organisations and healthcare professionals.
Medical interventions.
Quality and safety of healthcare.
Article 20 is particularly important because it regulates informed voluntary consent to medical intervention and refusal of medical intervention.
Application to precision medicine:
Before conducting certain genetic investigations or administering personalised treatment, healthcare providers must satisfy the applicable consent requirements.
For example, a patient undergoing pharmacogenomic testing should receive appropriate information about the purpose of testing, its medical relevance and the implications of the results.
Article 13 is also important because it regulates medical confidentiality.
A patient's genetic diagnosis, hereditary disease risk and other health-related information may fall within the protection of medical confidentiality.
B. Federal Law No. 61-FZ of 12 April 2010 – On the Circulation of Medicinal Products
This legislation regulates the development, clinical investigation, registration, production and circulation of medicinal products.
It is relevant to precision medicine because personalised treatment frequently involves medicines selected according to:
Genetic variations.
Molecular biomarkers.
Tumour mutations.
Drug-metabolism characteristics.
Individual therapeutic responses.
For example, a cancer medicine may be recommended only when molecular testing identifies a particular biomarker.
The applicable medicinal-product registration and safety requirements remain important even when the medicine is intended for a genetically defined patient population.
C. Federal Law No. 152-FZ of 27 July 2006 – On Personal Data
This law is particularly important for genomic medicine.
Precision medicine generates highly sensitive information, including:
DNA sequences.
Hereditary disease information.
Genetic susceptibility.
Molecular diagnostic results.
Patient-specific biological profiles.
Article 10 establishes special rules for processing special categories of personal data, including information concerning health, subject to statutory conditions and exceptions.
Article 19 addresses measures to ensure the security of personal data.
Legal significance: A genetic-testing laboratory cannot treat an individual's genomic information as ordinary commercial information. It must comply with the applicable personal-data requirements.
D. Federal Law No. 86-FZ of 5 July 1996 – On State Regulation in the Field of Genetic Engineering Activities
This legislation provides a regulatory framework for genetic-engineering activities.
Its relevance includes biotechnology research, genetic-engineering safety and the regulation of activities involving genetically engineered biological systems.
However, it should not be interpreted as a complete legal code for every form of human genomic testing or personalised medical treatment.
E. Federal Law No. 180-FZ of 23 June 2016 – On Biomedical Cellular Products
This legislation regulates biomedical cellular products intended for the prevention, diagnosis and treatment of diseases and for medical rehabilitation.
It covers important stages such as:
Development.
Preclinical research.
Clinical investigations.
State registration.
Manufacturing.
Quality control.
Storage and transportation.
Application and distribution.
This law is particularly relevant to personalised regenerative medicine and certain patient-specific cellular treatments.
cis-legislation.com+1
F. Federal Law No. 242-FZ of 3 December 2008 – On State Genomic Registration
This law regulates state genomic registration in Russia.
Its principal relevance is the collection, storage and use of genomic information for legally specified identification purposes.
It is important to distinguish state genomic registration from clinical genomic testing. A DNA profile collected for identification purposes is not automatically equivalent to a patient's complete medical genome or pharmacogenomic profile.
G. Ministry of Health Order No. 464n of 18 May 2021
This order establishes rules for conducting laboratory investigations.
It covers clinical laboratory investigations and provides for laboratory activities conducted by appropriately licensed medical organisations, including activities involving laboratory genetics.
It is particularly relevant to:
Genetic laboratory testing.
Molecular diagnostics.
Laboratory quality and procedures.
Clinical diagnostic investigations.
Professional responsibility for laboratory services.
The order is currently scheduled to remain in force until 1 September 2027, according to its published text.
Consultant Plus+1
4. Legal regulation of genetic testing and genomic sequencing
Genetic testing is one of the most important components of precision medicine.
It identifies genetic variations that may influence the development of diseases, the effectiveness of medicines and individual responses to treatment.
Russian precision-medicine practice may involve:
1. Whole-genome sequencing: Analysis of an individual's genetic material across the genome.
2. Whole-exome sequencing: Examination of protein-coding regions of DNA.
3. Pharmacogenomic testing: Identification of genetic variations that influence drug metabolism and response.
4. Hereditary cancer testing: Identification of inherited cancer-risk variants, such as BRCA1 and BRCA2 variants.
5. Molecular tumour profiling: Identification of tumour-specific mutations for targeted cancer treatment.
6. Prenatal genetic testing: Investigation of genetic or chromosomal conditions during pregnancy.
Legal responsibilities of genetic-testing laboratories
A laboratory conducting medical genetic investigations must pay attention to:
Applicable medical-activity licensing.
Appropriate laboratory qualifications.
Reliability and validation of testing procedures.
Proper handling of biological samples.
Confidentiality of patient information.
Accurate reporting of results.
Appropriate communication of clinically significant findings.
A false-positive genetic result could expose a patient to unnecessary treatment, while a false-negative result could delay preventive measures or appropriate medical intervention.
These circumstances may create questions of professional negligence and civil liability.
5. Pharmacogenomics and personalised drug treatment
Pharmacogenomics examines how genetic differences affect an individual's response to medicines.
For example, two patients suffering from the same disease may respond differently to an identical drug because of differences in drug-metabolising enzymes or other biological characteristics.
Precision medicine uses this information to help healthcare professionals select:
Appropriate medicines.
Suitable dosages.
Alternative treatments.
Safer treatment combinations.
More effective therapeutic strategies.
Legal issues
The main legal questions include:
Whether genetic testing was medically justified.
Whether the patient received adequate information.
Whether the medicine was properly authorised.
Whether the healthcare professional interpreted the results correctly.
Whether a known genetic risk was ignored.
Whether adverse drug reactions resulted from professional negligence.
Under Russian healthcare legislation, medical professionals must comply with applicable requirements for the quality and safety of medical assistance.
A genetic test does not automatically authorise a doctor to prescribe an unregistered medicine or disregard the applicable medicinal-product rules.
6. Precision oncology and targeted cancer treatment
Precision oncology is the application of genomic and molecular technologies to cancer treatment.
Traditional cancer treatment frequently relies on the location and stage of the tumour. Precision oncology additionally examines its molecular characteristics.
For example, molecular testing may identify mutations or biomarkers that indicate whether a patient is likely to benefit from a particular targeted therapy.
Precision Cancer Therapy | BioRender Science Templates
12
Legal framework in Russia
The principal legal framework includes:
Federal Law No. 323-FZ – healthcare and patient rights.
Federal Law No. 61-FZ – medicinal-product regulation.
Federal Law No. 152-FZ – personal-data protection.
Ministry of Health laboratory rules.
Applicable clinical recommendations and medical-care standards.
Important legal questions
A. Diagnostic accuracy
If a laboratory incorrectly identifies a tumour mutation, the patient may receive an unsuitable treatment.
B. Treatment selection
A doctor must consider the patient's clinical condition, the available evidence and applicable medical recommendations.
C. Pharmaceutical safety
Targeted medicines must comply with applicable registration and circulation requirements.
D. Medical negligence
If a healthcare professional ignores relevant test results or fails to exercise appropriate professional care, liability may arise depending on the circumstances and evidence.
7. Artificial intelligence and precision medicine
Artificial intelligence increasingly supports precision medicine through the analysis of large medical datasets.
Its potential applications include:
Genetic mutation identification.
Prediction of drug responses.
Cancer-risk assessment.
Medical image analysis.
Personalised treatment recommendations.
Biomarker identification.
Clinical decision support.
Genomic Revolution: AI Predicts Diseases from DNA
Legal concerns
AI-supported medical decision-making creates several legal challenges.
| Legal issue | Potential responsibility |
|---|---|
| Incorrect AI diagnosis | Medical organisation and relevant professionals |
| Biased genetic prediction | Developers and responsible deployers |
| Unlawful patient-data processing | Data controller or processor, as applicable |
| Unsafe medical software | Relevant manufacturer and regulatory actors |
| Failure to verify AI recommendations | Medical professional, depending on duties |
| Unauthorised secondary data use | Responsible data-processing organisation |
An AI-generated prediction should not automatically be treated as a clinically established diagnosis.
The applicable medical-device and software classification, registration and safety requirements must be considered where relevant.
8. Stem-cell therapy and personalised regenerative medicine
Personalised regenerative medicine seeks to repair or replace damaged tissues through biological and cellular technologies.
Potential applications include:
Patient-specific cellular products.
Regenerative treatments.
Tissue engineering.
Cellular therapies.
Personalised biological interventions.
Russia's Federal Law No. 180-FZ is particularly relevant to biomedical cellular products.
The statute establishes requirements concerning development, clinical investigations, registration, production and quality control.
Important legal principles
Informed consent: Patients must receive appropriate information about the proposed intervention and its risks.
Clinical safety: Experimental treatment must not be presented as an established treatment without appropriate legal and scientific justification.
Product quality: Cellular products must satisfy applicable regulatory and quality requirements.
Donor protection: Biological-material donation must comply with the applicable statutory framework.
Compensation: Patients may seek remedies where unlawful conduct or defective medical services cause legally compensable harm.
9. Protection of genetic data and patient privacy
Genetic information is particularly sensitive because it can reveal information about both the individual and biological relatives.
For example, genetic testing for hereditary cancer may disclose a possible inherited risk shared with parents, siblings and children.
Russia's principal legal protections include:
Constitution Articles 23 and 24.
Federal Law No. 152-FZ.
Federal Law No. 323-FZ, Article 13.
Applicable rules concerning medical records and information security.
Article 13 of Federal Law No. 323-FZ protects information concerning a patient's medical treatment, health condition and diagnosis.
The law also establishes circumstances in which disclosure is permitted without the patient's consent.
minzdrav.gov.ru+1
Example
Suppose a private laboratory conducts whole-genome sequencing for a patient and discovers a hereditary disease risk.
The laboratory subsequently transfers identifiable genetic information to a commercial organisation without an adequate legal basis.
This may raise questions involving:
Unlawful personal-data processing.
Breach of medical confidentiality.
Inadequate information security.
Civil liability.
Regulatory enforcement.
The fact that genetic information has scientific or commercial value does not remove the patient's applicable legal protections.
10. Important case laws and judicial precedents
An important research limitation must be recognised: Russia does not yet have a substantial, clearly established body of published judgments specifically addressing pharmacogenomics, precision oncology, whole-genome sequencing or AI-based personalised treatment.
Nevertheless, Russian constitutional decisions and European human-rights judgments concerning medical confidentiality, patient autonomy and genetic privacy provide important legal principles.
Case 1. Avilkina and Others v. Russia (2013)
Important Russian privacy precedent
Court: European Court of Human Rights.
Application No.: 1585/09.
Judgment date: 6 June 2013.
Legal provision: Article 8, European Convention on Human Rights.
Facts:
The case concerned the disclosure of confidential medical records of Jehovah's Witnesses who had refused blood transfusions.
Medical information was disclosed to prosecutorial authorities without the patients' consent.
Legal issue:
Whether the disclosure of confidential medical information without sufficient justification and safeguards violated the right to private life.
Judgment:
The European Court of Human Rights found a violation of Article 8.
It emphasised the fundamental importance of medical confidentiality and the need for adequate safeguards when medical information is disclosed.
Relevance to precision medicine:
This judgment is relevant to genomic testing laboratories and personalised healthcare providers.
For example, a hospital that discloses a patient's hereditary cancer-risk results or genetic disease profile without a proper legal basis may face similar privacy concerns.
Legal principle: Medical confidentiality must be protected against unjustified disclosure.
Primary judgment: Read Avilkina and Others v. Russia.
Case 2. Constitutional Court of the Russian Federation – Judgment No. 1-P of 13 January 2020
Russian constitutional precedent
Subject: Access to the medical records of deceased patients.
Facts:
The dispute concerned uncertainty in Russian healthcare legislation regarding access by a deceased patient's spouse, close relatives and other authorised persons to the deceased person's medical documentation.
Legal issue:
Whether the existing legal framework adequately protected constitutional rights while determining access to confidential medical records after a patient's death.
Decision:
The Constitutional Court found the relevant provisions unconstitutional to the extent that their uncertain legal content failed to establish sufficiently clear conditions and procedures for access.
It directed that, pending legislative changes, medical organisations should provide qualifying persons with access to the deceased patient's medical documentation, subject to the patient's expressed prohibition on disclosure.
Relevance to precision medicine:
This judgment is important for cases involving:
Hereditary disease investigations.
Genetic reports of deceased patients.
Familial cancer-risk information.
Access to historical genomic records.
Medical research involving inherited conditions.
For example, a deceased patient may have undergone genetic testing revealing a hereditary disease risk. The question of whether relatives may access relevant medical records must be considered under the applicable statutory rules and constitutional interpretation.
Legal principle: Medical confidentiality and family access to medical information must be reconciled through sufficiently clear legal rules.
Primary source: Constitutional Court judgment summary, No. 1-P (2020).
Case 3. Z v. Finland (1997)
Court: European Court of Human Rights.
Application No.: 22009/93.
Judgment date: 25 February 1997.
Legal provision: Article 8, European Convention on Human Rights.
Facts:
The case concerned the disclosure and retention of confidential medical information relating to a person's HIV status during criminal proceedings.
Legal issue:
Whether the disclosure and retention of highly sensitive medical information violated the right to respect for private life.
Legal significance:
The Court recognised that confidentiality of health information is a fundamental component of private life.
Relevance to precision medicine:
Genetic information may reveal hereditary disease susceptibility and biological relationships.
Consequently, the confidentiality principles developed in this judgment provide useful comparative guidance for protecting genomic information.
This is a Finnish case, not a Russian domestic judgment.
Case 4. S. and Marper v. United Kingdom (2008)
Court: European Court of Human Rights, Grand Chamber.
Applications Nos.: 30562/04 and 30566/04.
Judgment date: 4 December 2008.
Legal provision: Article 8, European Convention on Human Rights.
Facts:
The case concerned the retention of fingerprints, cellular samples and DNA profiles belonging to individuals who had not been convicted of criminal offences.
Legal issue:
Whether retaining sensitive biological and genetic identification information constituted a disproportionate interference with private life.
Judgment:
The Court found a violation of Article 8.
Relevance to precision medicine:
This decision is relevant to the storage of:
DNA samples.
Genomic profiles.
Biological specimens.
Genetic research databases.
Patient-identifiable molecular information.
It supports the importance of examining the purpose, scope and safeguards governing the retention of genetic material.
This is a comparative European precedent, not a Russian precision-medicine judgment.
Case 5. Lisitsa v. Medical Clinic – Moscow City Court, 2021
Court: Moscow City Court.
Appeal reference reported in secondary legal materials: No. 33-6546/2021.
Subject: Prenatal genetic testing and medical services.
Background:
The dispute concerned prenatal genetic testing and the scope of medical services provided by a private clinic.
The legal questions included the information supplied about the test and whether additional genetic counselling or investigations formed part of the contracted services.
Legal relevance:
This matter illustrates the importance of distinguishing between:
A screening test.
A diagnostic investigation.
Genetic counselling.
Additional clinical investigations.
A screening result does not necessarily constitute a definitive diagnosis.
Application to precision medicine:
A laboratory or clinic should clearly communicate the clinical purpose and limitations of genetic testing.
Patients should not be led to believe that a predictive or screening test guarantees a particular medical outcome.
Research qualification: The case reference and procedural history should be checked against the full court record before formal academic citation. It should not be presented as a Supreme Court ruling or as a general judicial doctrine on precision medicine.
11. Medical negligence and civil liability
Precision medicine creates new forms of potential medical liability.
A patient may suffer harm because of an incorrect genetic test, a defective diagnostic report, an inappropriate personalised prescription or the failure to respond to clinically significant test results.
Relevant provisions of Russian civil law include:
| Legal provision | Potential application |
|---|---|
| Civil Code Article 15 | Compensation for losses |
| Article 1064 | General liability for harm |
| Article 1095 | Liability for harm caused by defects in goods, work or services |
| Articles 1096–1098 | Related rules on compensation and grounds for exemption |
| Law No. 323-FZ, Article 98 | Liability in the sphere of healthcare |
Example 1: Incorrect genetic diagnosis
A laboratory reports that a patient does not carry a particular hereditary disease-associated variant.
Subsequently, another investigation identifies the variant, and the patient suffers harm because appropriate medical monitoring was delayed.
Potential legal questions include:
Was the laboratory procedure properly performed?
Was the testing method sufficiently reliable?
Were quality-control requirements followed?
Was the report professionally interpreted?
Can the patient's injury be causally connected to the laboratory's conduct?
Example 2: Incorrect pharmacogenomic prescription
A patient undergoes pharmacogenomic testing.
The results indicate a potentially important drug-metabolism variation, but the treating professional fails to consider it when selecting a medicine.
The patient develops a serious adverse reaction.
Depending on the circumstances, the dispute may involve professional negligence, causation, informed consent and compensation for harm.
Example 3: Defective personalised cellular treatment
A patient receives a cellular product that does not meet the applicable quality requirements.
The patient subsequently suffers an injury.
Federal Law No. 180-FZ and applicable civil-liability provisions may become relevant.
The existence of a scientific or technological innovation does not automatically exempt its provider from legal responsibility.
12. Ethical and regulatory challenges
Precision medicine creates several difficult legal and ethical questions.
A. Genetic discrimination
An individual's genetic information could potentially be misused in employment, insurance or other commercial decisions.
Russian law must be considered in relation to personal-data protection, medical confidentiality and applicable anti-discrimination protections.
B. Incidental genetic findings
Whole-genome sequencing may reveal unexpected medical information unrelated to the original investigation.
The law must be applied to questions concerning disclosure, consent and appropriate clinical communication.
C. Genetic information concerning relatives
A genetic test performed on one person may reveal hereditary risks affecting family members.
This creates a conflict between individual confidentiality and the potential medical interests of relatives.
D. Experimental personalised treatment
A treatment developed for an individual patient may still require regulatory authorisation, clinical investigation or other statutory compliance.
E. International genomic research
International collaboration may involve transferring biological samples and genetic datasets. Such activities require examination of applicable personal-data, research, biological-material and international-transfer rules.
13. Institutional authorities responsible for regulation
Several Russian institutions have responsibilities relevant to precision medicine.
| Institution | Principal responsibility |
|---|---|
| Ministry of Health | Healthcare policy and medical regulation |
| Roszdravnadzor | Healthcare supervision and relevant regulatory enforcement |
| Rospotrebnadzor | Public-health and sanitary oversight |
| Roskomnadzor | Personal-data protection supervision |
| Ministry of Industry and Trade | Relevant industrial and pharmaceutical policy |
| Federal Medical-Biological Agency | Medical and biological research and specialised healthcare functions |
Their respective responsibilities depend on the regulated activity.
14. Major legal problems and possible reforms
Russia's precision-medicine framework faces several important challenges.
| Legal challenge | Possible regulatory development |
|---|---|
| Genetic-data privacy | More detailed genomic-data safeguards |
| AI diagnostic errors | Clearer accountability for clinical AI |
| Incorrect genetic testing | Stronger laboratory quality assurance |
| Personalised drug treatment | Improved pharmacogenomic guidance |
| Precision oncology | Better coordination of molecular diagnostics and treatment |
| Stem-cell interventions | Effective safety and clinical oversight |
| Genetic discrimination | Clearer protections against misuse of genetic information |
| Cross-border genomic research | Transparent rules for international data cooperation |
| Incidental findings | Better consent and disclosure procedures |
A dedicated precision-medicine regulatory framework could clarify the responsibilities of laboratories, doctors, pharmaceutical manufacturers, biotechnology companies and medical-data processors.
15. Critical legal analysis
The Russian approach to precision medicine is based on the interaction of several legal regimes rather than a single specialised statute.
Three issues are particularly important.
First: Patient autonomy.
Precision medicine relies on collecting and interpreting highly personal biological information. The patient's right to receive information and participate in medical decisions is therefore essential.
Second: Scientific reliability.
Genomic sequencing and molecular diagnostics can improve medical decision-making, but inaccurate testing and inappropriate interpretation may cause significant harm.
Third: Genetic privacy.
Genetic information can reveal hereditary risks and information about biological relatives. Consequently, privacy protection must extend beyond ordinary medical record management.
The Russian legal framework provides statutory foundations for these issues, but the development of advanced genomic technologies creates new questions concerning accountability, data governance and the legal status of emerging medical technologies.
16. Important legal references
| Legislation / authority | Subject |
|---|---|
| Constitution of the Russian Federation | Constitutional healthcare and privacy rights |
| Federal Law No. 323-FZ (2011) | Healthcare, consent and medical confidentiality |
| Federal Law No. 61-FZ (2010) | Medicinal-product regulation |
| Federal Law No. 152-FZ (2006) | Personal-data protection |
| Federal Law No. 86-FZ (1996) | Genetic-engineering regulation |
| Federal Law No. 242-FZ (2008) | State genomic registration |
| Federal Law No. 180-FZ (2016) | Biomedical cellular products |
| Ministry of Health Order No. 464n (2021) | Laboratory investigations |
| Russian Civil Code | Medical and product-related civil liability |
17. Conclusion
Biotechnology Precision Medicine Law in Russia represents an important intersection of biotechnology, genetics, pharmaceutical regulation, medical ethics, constitutional rights and data protection.
The legal framework enables the development and application of genetic diagnostics, pharmacogenomics, precision oncology, personalised regenerative treatments and other advanced medical technologies.
However, technological advancement also creates legal responsibilities concerning patient consent, laboratory accuracy, clinical safety, genetic confidentiality and compensation for medical harm.
The decisions in Avilkina and Others v. Russia and Constitutional Court Judgment No. 1-P of 13 January 2020 are particularly useful for understanding the protection of medical confidentiality and access to medical records. Other European judgments provide comparative guidance concerning genetic and biological privacy.
Overall, the future of precision medicine in Russia depends on developing a regulatory balance between scientific innovation, individual autonomy, patient safety and responsible use of genetic information.
18. Research sources and case-law verification
For formal academic or legal research, the following primary sources should be consulted:
Russian Ministry of Health – Federal Law No. 323-FZ.
Article 20 – Informed voluntary consent.
Ministry of Health Order No. 464n.
Avilkina and Others v. Russia (2013).
Russian Constitutional Court Judgment No. 1-P (2020).
Important jurisdictional note: Russia ceased to be a party to the European Convention on Human Rights on 16 September 2022. Earlier ECHR judgments concerning Russia remain important historical authorities, but should not be described as establishing continuing Convention jurisdiction over subsequent Russian conduct.
The cases discussed above should also be distinguished from direct precision-medicine precedents: the Russian judicial framework specifically addressing modern pharmacogenomics and personalised genomic treatment remains limited.

comments